Dobutamine

Base Information

• Chemical Name: Dobutamine
• CAS No.: 34368-04-2
• Deprecated CAS: 67230-43-7
• Molecular Formula: C18H23NO3
• Molecular Weight: 301.386
• Hs Code.: 2922509090
• UNII: 3S12J47372
• DSSTox Substance ID: DTXSID3022958
• Nikkaji Number: J29.869G,J399.069I
• Wikipedia: Dobutamine
• Wikidata: Q422782
• NCI Thesaurus Code: C61733
• RXCUI: 3616
• Pharos Ligand ID: 733UWWYJS39L
• Metabolomics Workbench ID: 145572
• ChEMBL ID: CHEMBL926
• Mol file: 34368-04-2.mol

Synonyms:Dobucor;Dobuject;Dobutamin Fresenius;Dobutamin Hexal;Dobutamin ratiopharm;Dobutamin Solvay;Dobutamin-ratiopharm;Dobutamina Inibsa;Dobutamina Rovi;Dobutamine;Dobutamine (+)-Isomer;Dobutamine Hydrobromide;Dobutamine Hydrochloride;Dobutamine Lactobionate;Dobutamine Phosphate (1:1) Salt, (-)-Isomer;Dobutamine Tartrate;Dobutamine Tartrate (1:1), (R-(R*,R*))-Isomer;Dobutamine Tartrate (1:1), (S-(R*,R*))-Isomer;Dobutamine, (-)-Isomer;Dobutamine, Phosphate (1:1) Salt (+)-Isomer;Dobutrex;Hydrobromide, Dobutamine;Hydrochloride, Dobutamine;Lactobionate, Dobutamine;Lilly 81929;Oxiken;Posiject;Tartrate, Dobutamine

Chemical Property of Dobutamine

Chemical Property:

• Appearance/Colour: White or off-white crystalline powder
• Boiling Point: 527.7 °C at 760 mmHg
• Flash Point: 169.8 °C
• PSA: 72.72000
• Density: 1.189 g/cm³
• LogP: 3.34770
• Storage Temp.: 2-8°C
• XLogP3: 3.4
• Hydrogen Bond Donor Count: 4
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 7
• Exact Mass: 301.16779360
• Heavy Atom Count: 22
• Complexity: 305

Purity/Quality:

98%Min ^*data from raw suppliers

Dobutamine ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xn
• Hazard Codes: Xn
• Statements: 20/21/22-63
• Safety Statements: 22-26-36/37/39

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O
• Recent ClinicalTrials: Right Ventricular Contractile Reserve in HF
• Recent EU Clinical Trials: LEVO-MEMS: COMPARISION OF THE HAEMODINAMIC PROFILE OF DOBUTAMIN AND LEVOSIMENDAN IN THE CURRENT THERAPEUTICAL CONTEXT
• Recent NIPH Clinical Trials: Response to infusion of noradrenalin and dobutamine during head up tilt in cardiovascular autonomic dysfunction in patients with neurodegenerative disorder.
• Uses: Dobutamine is predominantly a β1-agonist, with some activity at β2- receptors. Its primary effect is an increase in cardiac output as a consequence of increased contractility and HR and decreased afterload. Systolic arterial pressure may therefore increase, but peripheral resistance is reduced or unchanged. It is primarily used as an inotrope (inodilator) in low CO states. D obutamine increases SA node automaticity and conduction velocity in the atria, ventricles and AV node, with tachyarrhythmias occurring at higher doses. Dobutamine is administered as an i.v. infusion at a dose range of 0.5– 40 μg kg–1 min–1. Cardiotonic.
• Therapeutic Function: Cardiotonic
• Clinical Use: #N/A
• Drug interactions: Potentially hazardous interactions with other drugsAnaesthetics: risk of ventricular arrhythmias with isoflurane - avoid.Antidepressants: risk of hypertensive crisis with MAOIs and moclobemide.Beta-blockers: possibly severe hypertension and bradycardia with non-cardioselective beta-blockers.Dopaminergics: effects possibly enhanced by entacapone; avoid with rasagiline.

Technology Process of Dobutamine

There total 5 articles about Dobutamine which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 89.8%

N-(3,4-dimethoxyphenethyl)-4-(4-methoxyphenyl)butan-2-amine (61413-44-3) → dobutamine (34368-04-2,61661-05-0)

Guidance literature:

N-(3,4-dimethoxyphenethyl)-4-(4-methoxyphenyl)butan-2-amine; With water; hydrogen bromide; acetic acid; for 6h; Heating / reflux;

With hydrogenchloride; In water; at 90 - 95 ℃; for 2 - 3h; Product distribution / selectivity;

Reference yield:

2-(3,4-dimethoxyphenyl)-ethylamine (120-20-7) + 4-(4-methoxyphenyl)-3-buten-2-one (3815-30-3) → dobutamine (34368-04-2,61661-05-0) + N-(3,4-dimethoxyphenethyl)-4-(4-methoxyphenyl)butan-2-amine (61413-44-3)

Guidance literature:

With hydrogen; aluminum nickel; palladium; In diethyl ether; ethyl acetate;

Reference yield:

3,4-dibenzyloxy-N-[3-(4-benzyloxy)-1-methyl-n-propyl]-β-phenylethylamine hydrochloride (1020073-90-8) → dobutamine (34368-04-2,61661-05-0)

Guidance literature:

With hydrogenchloride; hydrogen; 5%-palladium/activated carbon; In methanol; water; at 45 - 50 ℃; for 3h; Product distribution / selectivity;

upstream raw materials:

2-(3,4-dimethoxyphenyl)-ethylamine

4-(4-methoxyphenyl)-3-buten-2-one

N-(3,4-dimethoxyphenethyl)-4-(4-methoxyphenyl)butan-2-amine

3,4-dibenzyloxy-N-[3-(4-benzyloxy)-1-methyl-n-propyl]-β-phenylethylamine hydrochloride

Refernces

• 1、 -. "DRUG DISCHARGE PUMP INHIBITORS". . . Retrieved 2008/06/13.
• 2、 -. "Method for increasing cardiac contractility". . . Retrieved 2008/06/13.